Study of tunlametinib for advanced melanoma with NRAS mutation
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new oral targeted therapy (Tunlametinib) for people with advanced melanoma that has a specific gene change called NRAS. It's for those who have already tried immunotherapy and need another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced or metastatic melanoma that cannot be removed by surgery.
- You have a positive NRAS mutation from a genetic test.
- You have already tried immunotherapy (anti-PD-1/PD-L1) and it didn't work or you couldn't continue.
- You can take pills by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug (tunlametinib) for advanced thyroid cancer that has a specific genetic change called NRAS mutation. It may help people whose cancer is not responding to standard treatments like radioactive iodine.
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of two drugs for people with advanced pancreatic or colorectal cancer that has a specific genetic change called a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a combination of drugs for people with advanced lung cancer that has a specific genetic change called KRAS. The treatment aims to shrink tumors or slow their growth after standard treatments have stopped working.
Hear when a new Melanoma Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.